Go Pro
NASDAQ:TIL

Instil Bio Q1 2025 Earnings Report

Instil Bio logo
$7.04 -0.13 (-1.81%)
Closing price 09/28/2026 04:00 PM Eastern
Extended Trading
$7.10 +0.05 (+0.78%)
As of 09/28/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Instil Bio EPS Results

Actual EPS
-$4.32
Consensus EPS
-$2.02
Beat/Miss
Missed by -$2.30
One Year Ago EPS
N/A

Instil Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Instil Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Instil Bio's next earnings date is estimated for Monday, November 16, 2026, based on past reporting schedules.

Conference Call Resources

Instil Bio Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Instil Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Instil Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Instil Bio and other key companies, straight to your email.

About Instil Bio

Instil Bio (NASDAQ:TIL) is a clinical-stage biotechnology company focused on developing cell therapies for the treatment of cancer. The company’s research centers on tumor-infiltrating lymphocytes (TILs), immune cells that naturally recognize and attack cancer cells. Instil Bio aims to improve TIL therapies through its cell-engineering and manufacturing capabilities, with the goal of producing treatments that are more potent, consistent and scalable.

The company’s pipeline has included genetically modified TIL candidates designed to enhance anti-tumor activity and address limitations associated with conventional TIL therapies. Its programs have been investigated for the treatment of solid tumors, an area in which developing effective cellular immunotherapies remains challenging.

Instil Bio was established in 2018 and has operated as a U.S.-based biotechnology company, with research and development activities supported by cell-therapy expertise in the United States and the United Kingdom. Its programs remain in clinical development, and the company’s work is focused primarily on advancing engineered TIL therapies toward potential commercialization.

View Instil Bio Profile